Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565283 | 1.00 | FNTA (0.35) | FNTAFNTBPGGT1BCYP3A4CYP2C19 | |
| SCHEMBL7561738 | 0.91 | ITGB3 (0.33) | ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL7590669 | 0.90 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL7563965 | 0.90 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL7561326 | 0.90 | PTGS2 (0.40) | FNTAFNTBPGGT1BCYP3A4CYP2C19 | |
| SCHEMBL7562685 | 0.90 | PTGS2 (0.40) | FNTAFNTBPGGT1BCYP3A4CYP2C19 | |
| SCHEMBL7562561 | 0.86 | ITGB3 (0.33) | FNTAFNTBPGGT1BITGB3ITGB1 | |
| SCHEMBL7561741 | 0.86 | CYP24A1 (0.37) | FNTAFNTBPGGT1BITGB3ITGB1 | |
| SCHEMBL7561297 | 0.84 | TBXAS1 (0.38) | CYP3A4CYP2C9PTGS2TBXAS1 | |
| SCHEMBL7568948 | 0.83 | KDM4E (0.38) | CYP3A4CYP2C9PTGS2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | FNTA 1/4885FNTB 2/4885PGGT1B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.